Teva Says GSK Skinny Label Win Will Have 'Seismic' Impact
The Federal Circuit's second holding that Teva induced doctors to infringe a patent for GlaxoSmithKline's drug Coreg, despite allegedly carving out the only patented-protected treatment from its label, will have a...To view the full article, register now.
Already a subscriber? Click here to view full article